LEAPS Technology
Rheumatoid Arthritis
Key Facts
About CEL-SCI
CEL-SCI is a publicly traded biotech company (NYSE American: CVM) founded in 1983, dedicated to developing immune-based therapies for cancer, autoimmune, and infectious diseases. Its core strategy involves activating the immune system at the point of diagnosis, before the immune system is compromised by conventional treatments. The company's landmark global Phase 3 trial in head and neck cancer, one of the largest ever in the indication, demonstrated a 14.1% absolute overall survival advantage at five years, positioning Multikine for a potential regulatory filing and a new treatment paradigm in oncology.
View full company profileAbout CEL-SCI
CEL-SCI is a publicly traded biotech company (NYSE American: CVM) founded in 1983, dedicated to developing immune-based therapies for cancer, autoimmune, and infectious diseases. Its core strategy involves activating the immune system at the point of diagnosis, before the immune system is compromised by conventional treatments. The company's landmark global Phase 3 trial in head and neck cancer, one of the largest ever in the indication, demonstrated a 14.1% absolute overall survival advantage at five years, positioning Multikine for a potential regulatory filing and a new treatment paradigm in oncology.
View full company profileAbout CEL-SCI
CEL-SCI is a publicly traded biotech company (NYSE American: CVM) founded in 1983, dedicated to developing immune-based therapies for cancer, autoimmune, and infectious diseases. Its core strategy involves activating the immune system at the point of diagnosis, before the immune system is compromised by conventional treatments. The company's landmark global Phase 3 trial in head and neck cancer, one of the largest ever in the indication, demonstrated a 14.1% absolute overall survival advantage at five years, positioning Multikine for a potential regulatory filing and a new treatment paradigm in oncology.
View full company profileTherapeutic Areas
Other Rheumatoid Arthritis Drugs
| Drug | Company | Phase |
|---|---|---|
| Early Detection Test for Rheumatoid Arthritis | Age Labs | Development |
| CORTONE (cortisone) | Merck | Commercial |
| Kevzara (sarilumab) | Regeneron Pharmaceuticals | Approved |
| Actemra (tocilizumab) | Chugai Pharmaceutical | Approved |
| Tocilizumab | Biocon | Filed |
| Humira | Abbott India | Approved |
| KPL-404 | Kiniksa Pharmaceuticals | Phase 2 |
| Tibulizumab (ZB-106) | Zura Bio | Phase 1b |
| Zunsemetinib (ATI-450) | Aclaris Therapeutics | Phase 2b |
| Natrunix Program | XBiotech | Not Specified |
| Piclidenoson (CF101) | Can Fite Biopharma | Phase 3 |
| Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure) | LFB | Pre-clinical |